ライフサイエンスコーパス: dropout

1 kg with the restricted normal-food diet (26% dropout).

2 omized with 33 in each arm (accounting for 2 dropouts).

3 outs) and biological mesh closure (n = 50; 2 dropouts).

4 patient characteristics and rate of waitlist dropout.

5 treatment groups, even after accounting for dropout.

6 xed-effects model accounting for informative dropout.

7 and contact lens use and selection bias from dropout.

8 ecovery, other interview-based outcomes, and dropout.

9 analyses; 18 of these had relapsed prior to dropout.

10 and survival model to adjust for informative dropout.

11 n static over the next decade due to patient dropout.

12 allowed for the extrapolation of the risk of dropout.

13 ferences between groups after accounting for dropout.

14 yping errors from sources other than allelic dropout.

15 n 11 (P=0.04) were independent predictors of dropout.

16 ytical challenges, such as outcome-dependent dropout.

17 which two demonstrated evidence of mecA gene dropout.

18 trait interrelatedness, and random genotype dropout.

19 s diabetic renal injury, especially podocyte dropout.

20 salvaged by OLT), without resultant death or dropout.

21 o prevent tumor progression and thus prevent dropout.

22 nfection was characterized by hepatocellular dropout.

23 with pericyte (vascular smooth muscle cell) dropout.

24 erience an increase from 53% to 64% waitlist dropout.

25 mbrane thickening, albuminuria, and podocyte dropout.

26 ach to achieve the target dose without early dropout.

27 ter retinal tubulations and choriocapillaris dropout.

28 fter listing) owing to tumor progression and dropout.

29 cially for males and children of high school dropouts.

30 ox, arbitrary choice of threshold value, and dropouts.

31 on of artefenomel) but there were no further dropouts.

32 outs, and insufficient response: 26 (33%) of dropouts.

33 ." RESULTS: There were no deaths or patients dropouts.

34 B/RIF group were on treatment due to reduced dropout (15 [8%] of 185 in the MTB/RIF group did not rec

35 38% vs. 22%; P = 0.017) and a higher risk of dropout (22% vs. 8%; P = 0.01).

36 he outcomes and no difference in participant dropout (24.5% in PE and 20.0% in EMDR, P = .57).

37 t and CABG patients had similar rates of CRP dropout (27.9% vs. 37.2% respectively, P=0.4).

38 iectasias (40.6%), lid debris (50.9%), gland dropout (42.8%), and acini appearance (54.5%).

39 ges were -11.4 +/- 9.1 kg with the VLCD (18% dropout), -6.8 +/- 6.4 kg with the LCD (23% dropout), an

40 Overall, the ARMS-qPCR had frequent allele-dropout (ADO), rendering it inappropriate as the sole di

41 treating extensive BCLM with the pitfall of dropout after the first stage.

42 ies by comparative genomics methods based on dropout alignments.

43 egraded evidence leading to allele and locus dropout; allele sharing of contributors leading to allel

44 s, have introduced new problems such as data dropout and "information overload" for the clinical team

45 ent randomized trials did not handle patient dropout and "rescue" medication properly.

46 Vascular dropout and angiogenesis are hallmarks of the progressio

47 Measures of capillary dropout and capillary hemodynamics were also quantified.

48 on heterogeneity but suffers from stochastic dropout and characteristic bimodal expression distributi

49 The high rate of subject dropout and data management errors substantially reduced

50 ter program, Pedant, which estimates allelic dropout and false allele error rates with 95% confidence

51 rrently methods to estimate rates of allelic dropout and false alleles depend upon the availability o

52 tween two distinct classes of error, allelic dropout and false alleles.

53 family involvement is important in limiting dropout and improving outcomes.

54 ral smoothing, thereby decreasing the signal dropout and increasing the temporal signal-to-noise rati

55 gostino Kaplan-Meier approach to account for dropout and loss to follow-up before 10 years.

56 Rates of dropout and loss to follow-up were low (6.3%), and the a

57 Participant dropout and lower-than-expected disease event rate limit

58 g units and deep learning techniques such as dropout and momentum training to accelerate the DNN trai

59 Gland dropout and potentially lid telangiectasia grading from

60 cytes and proximal tubules prevents podocyte dropout and reductions in nephrin levels in diabetic mic

61 signal was digitally filtered for noise and dropout and reported using time-window averaging for 19,

62 ation of exogenous Epo prevented both vessel dropout and subsequent hypoxia-induced neovascularizatio

63 ity analyses examining the effect of patient dropout and treatment adherence did not alter the result

64 t tests except for grids with 70% random dot dropout and two gray levels.

65 Compared with placebo, more dropouts and adverse events (anorexia, nausea, vomiting,

66 Dropouts and adverse events were limited and did not dif

67 fect among GT 2/3 patients, who showed fewer dropouts and higher SVR rates.

68 The primary endpoint was analyzed without dropouts and was reached in 43% (7 of 16) of the control

69 are subject to stochastic effects, such as "dropout" and "dropin" of alleles, and highly variable st

70 domly assigned to primary closure (n = 54; 1 dropouts) and biological mesh closure (n = 50; 2 dropout

71 dropout), -6.8 +/- 6.4 kg with the LCD (23% dropout), and -5.1 +/- 5.9 kg with the restricted normal

72 computed according to the predicted risk of dropout, and drop-out equivalent MELD (deMELD) points we

73 ariable risks of tumor progression, waitlist dropout, and posttransplant recurrence.

74 orbidity, including suicide attempts, school dropout, and substance abuse, but many depressed adolesc

75 methods to account for missing data, patient dropout, and use of rescue medication.

76 nd one missed mutation resulting from allele dropout, and we characterized the pattern of deep intron

77 events or intercurrent illness: 27 (34%) of dropouts, and insufficient response: 26 (33%) of dropout

78 aluation of the dropout rate and reasons for dropout are important not only in the planning of clinic

79 The RPE in regions of vascular dropout are presumably hypoxic, which may result in an i

80 -term trends in density while accounting for dropout as well as for measurement error.

81 Treating all dropouts as relapse to baseline, topiramate was more eff

82 een groups with no significant difference in dropouts attributable to adverse events.

83 e in the placebo group); the main reason for dropout before completion was because of adverse events.

84 median follow-up was 31 months (IQR 14-62); dropout before starting antiretroviral therapy or AIDS o

85 Our aim was to identify predictors of dropout before transplantation and predictors of cancer

86 for measured confounders and determinants of dropout by inverse probability weighting, the full cohor

87 Participant dropouts can reduce the power of allergen immunotherapy

88 ted a self-reported survey on factors behind dropout cases and poor adherence cases.

89 Our method considers estimates of allelic dropout caused by both sample-specific factors and locus

90 lthy participants, likely due to fMRI signal dropout caused by the air/bone interface of the petrous

91 )nalysis (ZIFA), which explicitly models the dropout characteristics, and show that it improves model

92 e 1- and 2-year cumulative probabilities for dropout (competing risk) were 24.1% and 34.2% in the dow

93 ography, spirometry, 6-minute-walk distance, dropouts, compliance, and side effects were evaluated.

94 trodecrement and paraspinal electromyography dropout consistent with atonic seizures.

95 Focal capillary dropout could be visualized in the SVC, but not the ICP

96 t least 3 dots/charwidth were presented, and dropout did not exceed 50%.

97 ied as muscle wasting diseases with myofiber dropout due to cellular necrosis, inflammation, alterati

98 In patients with a higher risk of dropout due to GT 1/4 or mental distress, PE was shown t

99 ignificant reduction in the risk of waitlist dropout due to progression (relative risk [RR], 0.32; 95

100 measures of pain at rest, walking pain, and dropouts due to adverse effects.

101 n the yoga group; serious adverse events and dropouts due to adverse events were comparable between g

102 nonserious, or serious adverse events and of dropouts due to adverse events were found when comparing

103 Adverse events (most mild or moderate) and dropouts due to adverse events were more common with nal

104 d by multiple averse factors, notably signal dropouts due to magnetic inhomogeneity and low signal-to

105 e associated with an increased likelihood of dropouts due to side effects (meta-regression: beta=0.00

106 of the study was to quantify weight loss and dropout during a commercial weight-loss program in Swede

107 ifferences in inclusion criteria and patient dropout during the study.

108 tment failure, recurrence, or death or study dropout during treatment) measured 24 months after the e

109 he important roles of Ang-2-induced pericyte dropout during tumor vessel regression.

110 nder what conditions of treatment uptake and dropout elimination of HIV is feasible.

111 d, including the computational management of dropout events, the reconstruction of biological pathway

112 duction methods because of the prevalence of dropout events, which lead to zero-inflated data.

113 ial confounders, missing covariate data, and dropout, ever-use of two pesticide classes, fumigants an

114 quencing, as they do not account for allelic dropout, false-positive errors and coverage nonuniformit

115 ms, categorical response to treatment, study dropout for any reason and for inefficacy of treatment,

116 ophrenia, categorical response to treatment, dropouts for any reason and for inefficacy of treatment,

117 area less than 17% of the target image, 70% dropout, four or fewer gray levels, and a gap of 40.5 ar

118 LD scores, will have an increase in waitlist dropout from 30% to 44%.

119 [CI], 0.06-1.85; I(2) = 0%) and of waitlist dropout from all causes (RR, 0.38; 95% CI, 0.060-2.370;

120 In one series, the rate of dropout from all causes at 6 months in T1 HCC patients w

121 Selective dropout from graft failure did not affect the cell loss

122 Carlo) accounted for missing data, selective dropout from graft failure, correlations between fellow

123 to side effects could be a factor affecting dropout from SLIT.

124 sidered the factors of poor adherence to and dropout from sublingual immunotherapy (SLIT) by verifyin

125 liver disease may lead to increased risk of dropout from the liver transplant waitlist.

126 tes of failure to adhere to the protocol and dropout from the study, the greater the risk of bias.

127 Dropout from the transplant list was equal in both group

128 5 to 34 years were less likely to experience dropout from the waiting list compared with those aged 1

129 etwork Organ Sharing priority; nevertheless, dropout from the waiting list is common.

130 s for cadaveric livers, however, may lead to dropout from the waiting list or worsened post-OLT progn

131 Dropout from treatment was higher in trauma-focused grou

132 ne drug screens and self-report) and time to dropout from treatment.

133 olates showed results compatible with a mecA dropout genotype.

134 foveal avascular zone, perifoveal capillary dropout grade, and presence of morphologic features of d

135 Time to dropout had a significant main effect of dose, with mean

136 t, intention-to-treat analysis, and adequate dropout handling.

137 Post-mortem ganglion cell dropout has been observed in multiple sclerosis; however

138 loss of MMP-12 attenuated retinal capillary dropout in early OIR and mitigated pathological retinal

139 LRT mitigates tumor progression and waitlist dropout in HCC patients within MC, but data on its impac

140 cell death contributed to the cardiomyocyte dropout in Jup mutant hearts.

141 Factors predicting dropout in the downstaging group included pretreatment a

142 To overcome the fMRI signal dropout in the neighborhood of the NFA, we combined high

143 tion methods to account for the high rate of dropouts in all 3 groups yielded similar results.

144 There were no dropouts in this group and all 3 patients were assessed

145 disease progression, serious adverse events, dropouts) in pivotal trials.

146 Predictors of dropout include multiple tumors and tumors with a diamet

147 One general approach for avoiding allelic dropout involves repeated genotyping of homozygous loci

148 Allelic dropout is a commonly observed source of missing data in

149 Risk of dropout is related to patient and tumor characteristics

150 , 0.16-0.32) to moderate agreement for gland dropout (kappa(w) = 0.50, 0.40-0.59) and telangiectasias

151 4 individuals, missing data and differential dropout, limited ethnic and racial diversity, and differ

152 ng 252 subjects, at 4 months, there were 30% dropouts, mainly due to side-effects.

153 ies aimed at preventing or delaying pericyte dropout may avoid or attenuate the retinal microangiopat

154 ipants (n = 33) were censored at the time of dropout, mean cumulative response rate for escitalopram

155 and counterselection of ura3 using a uracil dropout medium and 5-fluoroorotic acid.

156 cherichia coli serC mutant to grow in serine-dropout medium, demonstrating that M. tuberculosis serC

157 =2.98) and decreased likelihood of all-cause dropout (meta-regression: beta=-0.00093, 95% CI=-0.00165

158 erms of a stringent p-value) obtained by the dropout method by comparing them to null models construc

159 igning sequences after modifying them by the dropout method, i.e., by disregarding poly(N) runs durin

160 ltiple imputations of alleles in cases where dropout might have occurred.

161 nclear reporting for allocation concealment, dropouts, missing data on outcomes, and heterogeneity in

162 Neuronal damage and dropout must therefore be due to indirect effects of HIV

163 The rate of mecA/mecC dropout mutants was also evaluated.

164 nformation and takes into account of allelic dropouts, null alleles and prior knowledge of inbreeding

165 Abnormalities and vascular dropout observed within the choriocapillaris for pvOCT a

166 Dropouts occurred due to palpitations (one patient on el

167 plet MDA product to achieve a median allelic dropout of 15%, and using whole genome sequencing to ach

168 icant main effect of dose, with mean time to dropout of 27, 36, and 48 days for the placebo, 192 mg o

169 cant decrease in density of RGCs, as well as dropout of axons within the optic nerve at 8 weeks after

170 The risk of dropout of HCC patients was independently predicted by M

171 Results indicate that aging mice show dropout of meibomian glands with loss of gland volume an

172 magnetic resonance imaging leads to greater dropout of patients over time because of device implanta

173 Despite substantial dropout of patients, the healing pattern in event-free S

174 ding diabetes causes renal injury with early dropout of podocytes, albuminuria, glomerular and tubulo

175 ieve comparable OS and DFS, despite the high dropout of the 2-stage strategy.

176 relativistic energies and produce a profound dropout of the ultra-relativistic radiation belt fluxes.

177 ricular (AV) node and then develop selective dropout of these conduction cells.

178 nd depression symptoms, potential for school dropout) of DSPD, as several biological features underpi

179 is evolving to reduce tumor progression and dropout on the list as well as to influence posttranspla

180 An increased risk of dropout on the waiting list can be expected, but with eq

181 Overall, only two dropouts (one rebound activity and one gastrointestinal

182 Methods used to account for selective dropout only marginally changed these observed associati

183 who enrolled had surgery, and there were no dropouts or patients lost to follow-up.

184 ths; treatment failure; hospitalization; and dropout owing to any cause, non-adherence and intolerabi

185 SGAs showed trend-level superiority for dropout owing to intolerability (P=0.05).

186 should be regarded as a major risk factor of dropout owing to tumor progression and should be taken i

187 as the only other independent risk factor of dropout owing to tumor progression.

188 Group A exhibited 1 dropout patient and 1 failure, resulting in a survival r

189 Including dropout patients from LT list in the analysis, the outco

190 good and poor adherence groups, except four dropout patients, the adherence tended to be poor in pat

191 ppear to be a major problem with a composite dropout percentage of 14% (95% CI:11.9-16).

192 rs (dot size, grid size, dot spacing, random dropout percentage, and gray-scale resolution).

193 r eventually leading to glomerular capillary dropout (rarefaction) and further increases in intraglom

194 The dropout rate (15/313) was low.

195 These findings are limited by a high dropout rate (34%) and by suboptimal dietary adherence o

196 baseline or during the study, or annualised dropout rate (7.7% [95% CI 6.2-9.5] for vaccine recipien

197 al group, those in the TES group had a lower dropout rate (hazard ratio=0.72, 95% CI=0.57, 0.92) and

198 w initial weight loss predicted an increased dropout rate (P < 0.001).

199 arried out in order to establish the overall dropout rate among published double-blind, placebo-contr

200 Tumor-related dropout rate and post-OLT outcome compared favorably wit

201 Evaluation of the dropout rate and reasons for dropout are important not o

202 T1 HCC patients who did not receive LRT, the dropout rate at median follow-up of 2.4 years and the pr

203 on as it was likely impacted by an increased dropout rate before treatment, which led to crossover th

204 The dropout rate due to AEs was 8.3%.

205 his study (8.0 vs. 9.1, P<0.02), and a lower dropout rate due to intolerance (12.5 percent vs. 20.6 p

206 -month regimen, was associated with a higher dropout rate during treatment (5.0% vs. 2.7%) and more t

207 ad for HSC and researchers, and increase the dropout rate for proposed studies when investigators are

208 median adherence was 97.6% after 1 year; the dropout rate for treatment-related AEs was 0.9%.

209 Only 2 (14%) of 14 studies reported a dropout rate greater than 0%.

210 The overall dropout rate in the 22 selected trials was 12.4%.

211 al-therapy group, P=0.009) owing to a higher dropout rate in the medical-therapy group.

212 he medical-therapy group), owing to a higher dropout rate in the medical-therapy group.

213 1.1, 6.3) were associated with an increased dropout rate in the VLCD group.

214 n anemia but is poorly tolerated (an adverse dropout rate of > 50% in 3 months).

215 culated as 35 patients for each group with a dropout rate of 10%.

216 ion group had a significantly higher overall dropout rate than the monotherapy groups but did not hav

217 dividuals completed the 24-wk study, and the dropout rate was 27%.

218 cases, 21 (17%) were withdrawn; the overall dropout rate was 46% (56/122) in the remaining patients.

219 The dropout rate was high (11 of 25) in the pirfenidone 2400

220 The dropout rate was higher in the lithium/sertraline combin

221 On an intention-to-treat basis, the dropout rate was higher in the M+ group and the 5-year a

222 The STAIR/Exposure dropout rate was lower than the rate for the exposure co

223 The dropout rate was more pronounced in the Everolimus group

224 The dropout rate was similar to regular cognitive behavior t

225 Response rates and acceptability (dropout rate).

226 The grid size, dot size, gap width, dot dropout rate, and gray-scale resolution were varied sepa

227 chemical response (as measures of efficacy), dropout rate, and lamivudine resistance (as measures of

228 However, the trial was limited by a high dropout rate, and longer-term neurological and metabolic

229 rcise training was well tolerated with a low dropout rate, and no major adverse events were related t

230 Due to the high dropout rate, only 31 individuals were evaluated.

231 Small sample size and appreciable dropout rate.

232 ytopenia, and predicted a higher therapeutic dropout rate.

233 d while enrollment was ongoing due to a high dropout rate.

234 a primary care setting is hampered by a high dropout rate.

235 ample weighting methods accounted for higher dropout rates among ethnic minorities and those with low

236 Differing characteristics predict dropout rates and acceptance, which need to be carefully

237 zation algorithm to jointly estimate allelic dropout rates and allele frequencies when only one set o

238 approach to reliably model the cell-specific dropout rates and amplification bias by use of external

239 Secondary outcomes were dropout rates and measures of personality disorder trait

240 Dropout rates and occurrence of adverse events did not d

241 In contrast, psychotherapy trials had lower dropout rates and provided follow-up data.

242 mania or hypomania, and tolerability (using dropout rates as a proxy).

243 ning new PhDs is complex and has significant dropout rates associated with loss of financial and time

244 Dropout rates did not differ between groups, and treatme

245 BT-I group, the standard DBT group had lower dropout rates from treatment (8 patients [24%] vs 16 pat

246 ctive direct analysis of both recurrence and dropout rates in comparable patient cohorts with HCC und

247 Relative dropout rates in placebo and active groups as well as re

248 Dropout rates in sublingual immunotherapy controlled stu

249 No between-group differences in dropout rates or patients' ratings of satisfaction with

250 Acceptance of treatment and relatively high dropout rates pose a major problem for research in the t

251 High treatment dropout rates suggest the importance of improving retent

252 The dropout rates were 49.4% in the MMT+P and 26.3% in the M

253 s reports of stomach upset and headache, yet dropout rates were comparable between groups.

254 Dropout rates were highest in the first 12 to 18 months

255 ample-specific dropout rates, locus-specific dropout rates, and the inbreeding coefficient; and (3) s

256 High dropout rates, dosing inequalities, small sample sizes,

257 model parameters, including sample-specific dropout rates, locus-specific dropout rates, and the inb

258 likelihood of more rapid efficacy may reduce dropout rates.

259 m of treatment), and monitoring differential dropout rates.

260 ll efficacy (primary outcome); responder and dropout rates; positive, negative, and depressive sympto

261 between good adherence, poor adherence, and dropout regarding level of understanding of the treatmen

262 ple data set (for example, because of animal dropout), repeated-measures analysis of covariance may f

263 ch causes poor compliance and high treatment dropout, resulting in the development of drug-resistant

264 Nearly half of the dropouts returned for their 16- and 30-month radiographs

265 We carried out dropout screens for shRNAs that affect cell proliferatio

266 rmed whole-genome small hairpin RNA (shRNA) "dropout screens" on 77 breast cancer cell lines.

267 In addition, the metrics of capillary dropout showed small changes (between 3% and 7%), leukoc

268 multiple replicates with different rates of dropout, sporadic dropins, different amounts of DNA from

269 behavioral therapy was associated with fewer dropouts than pill placebo or medications.

270 for measured confounders and determinants of dropout, the weighted hazard ratio for acquired immunode

271 died (1 UC patient and 4 HNC patients after dropout); thus, uncensored hazard ratio was 0.62 (0.40-0

272 ing (outcome), co-interventions, compliance, dropouts, timing, and intention to treat.

273 ies with variable surveillance protocols and dropout to active treatment.

274 y apparent bias due to the effects of allele dropout typical of RAD data.

275 arceration, suicide, school difficulties and dropout, unemployment, and poor interpersonal relationsh

276 orthopaedic care group; the main reason for dropout was death.

277 mecA dropout was detected in 9/130 (6.9%) patients.

278 idal neovascularization (CNV) in wet AMD, CC dropout was evident in the absence of retinal pigment ep

279 s (4 vs. 7 months P=0.04) but hazard rate of dropout was higher (26%, 46%, and 73% at 6,12, and 24 mo

280 Risk of dropout was higher for patients beyond Milan, but within

281 Dropout was lower in the schema therapy and clarificatio

282 VEN dropout was not attributable to general neuronal loss an

283 Waitlist dropout was observed in 18.4% at a median of 11.3 months

284 om exceeding 50% and poor outcomes following dropout, we must explore innovative strategies for enhan

285 To account for dropouts, we applied a pattern-mixture model.

286 The most frequent reasons for dropout were adverse events or intercurrent illness: 27

287 ebo and active groups as well as reasons for dropout were also assessed.

288 Demographic predictors of treatment dropout were also examined.

289 Predictors of dropout were carbohydrate antigen 19-9 (CA 19-9) >/= 500

290 angiogenesis/neovascularization and vascular dropout were dominated first by remodeling of arteries a

291 Reasons for participant dropout were loss to follow-up and withdrawal of consent

292 Dropouts were analysed in regards to allergen, formulati

293 Dropouts were similar between groups, and compliance and

294 dinal studies are complicated by participant dropout, which could be related to the presence of psych

295 The hazard of dropout will increase from 41% to 46% nationally.

296 orderzone sign-that is, bilateral ASL signal dropout with surrounding cortical areas of hyperintensit

297 ical trials involving 10 to 120 patients (no dropouts) with early to moderately advanced prion diseas

298 phy demonstrated variable areas of capillary dropout within the superficial and deep retinal capillar

299 Submacular CC dropout without retinal pigment eipthelial (RPE) loss wa

300 gion lies within or close to the fMRI signal-dropout zone produced by the nearby auditory canal and v